Rezolute releases Phase 2 topline results for RZ402 in DME; no specifics in filing

Rezolute, Inc.

Topline results from Phase 2 study of RZ402 in diabetic macular edema (DME) disclosed via website and SEC filing on June 28, 2024.
Presentation originally provided during May 21, 2024 investor webcast; appendix added on June 28, 2024.
Actual efficacy or safety data (e.g., p-values, responder rates) are not visible in the available 8-K or exhibit text.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.